Mindray won CNY 15.46 million award and analysts set target for Mindray stock
Published on 10/13/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Mindray won CNY 15.46 million in patent compensation across four cases dated October 7, 2026.
- The first half of 2026 brought revenue of RMB 17.747 billion, up 6.00 percent year over year.
- Mindray stock was last at CNY 164.94 on the Shenzhen Stock Exchange on October 13, 2026, with a CNY 280.14 average analyst target.
- International revenue rose 13.67 percent in the first half of 2026, while net profit attributable to shareholders fell 5.37 percent.
Mindray won CNY 15.46 million in patent compensation across four cases on October 7, 2026, as iNEWS reported. An October 2026 analyst overview lists an average target of CNY 280.14 for Mindray stock, based on 32 ratings, according to Eulerpool.
Three events shape the picture
On September 15, 2026, Mindray North America launched the SV70 non-invasive ventilator in the United States, adding a respiratory-care product to the company's portfolio, according to Mindray.
On September 30, 2026, Citic Securities described the second quarter as a performance inflection point. Its report said second-quarter revenue reached RMB 9.395 billion, up 10.45 percent year over year, while net profit attributable to shareholders rose 1.10 percent to RMB 2.467 billion, per Futu.
On October 7, 2026, the patent cases supplied a separate legal and commercial data point. The CNY 15.46 million award covered four invention-patent infringement cases involving Mindray, Coman Medical and Chenrui Medical, according to iNEWS.
What does second-quarter growth change?
The operating mix provides the clearest answer. First-half 2026 revenue was RMB 17.747 billion, up 6.00 percent year over year, while net profit attributable to shareholders was RMB 4.797 billion, down 5.37 percent, according to Futu.
International revenue reached RMB 9.471 billion, up 13.67 percent, and represented 53 percent of total revenue. Emerging businesses generated RMB 3.110 billion, up 19.59 percent, while in-vitro diagnostics revenue rose 9.58 percent to RMB 6.865 billion.
The counterweight is margin pressure. Gross margin declined to 60.83 percent in the first half of 2026, down 0.84 percentage points, while the financial expense ratio rose 4.16 percentage points to 2.16 percent, with foreign-exchange effects cited in the report.
Mindray stock stays below its high
Mindray was last at CNY 164.94 on the Shenzhen Stock Exchange on October 13, 2026 at 3:04 p.m. CST. The same market snapshot puts market capitalization at CNY 200.0 billion and the 52-week range at CNY 130.66 to CNY 239.79, leaving the share price CNY 74.85 below the yearly high.
The average analyst target of CNY 280.14 stands 69.85 percent above the CNY 164.94 market price, while the current operating picture combines 13.67 percent international revenue growth with a 5.37 percent decline in first-half net profit.
Market context: Market report Shanghai Composite.
Mindray stock facts
- Company: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- ISIN: CNE100003G67
- Ticker: 300760.SZ
- Primary exchange: Shenzhen Stock Exchange
- Price Shenzhen Stock Exchange: CNY 164.94 as of October 13, 2026 at 3:04 p.m. CST
- Market capitalization: CNY 200.0 billion as of October 13, 2026
- 52-week range: CNY 130.66-CNY 239.79 as of October 13, 2026
- Sector / Industry: Healthcare / Medical Devices
